Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Table 3 Impact of [¹⁸F]flutemetamol PET on patient management according to clinical diagnosis prior to PET

Pre-PET etiology	AD (n = 145)		FTD (n = 28)		OD (n = 19)		NN (n = 20)
PET result	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
n	111	34	6	22	8	11	9	11
AD medication	39 (35%)^a	1 (3%)	3 (50%)^a	0 (0%)	1 (13%)	0 (0%)	6 (67%)^a	1 (9%)
Care	12 (11%)	1 (3%)	1 (17%)	1 (5%)	0 (0%)	0 (0%)	4 (44%)	3 (27%)
Ancillary investigations	0 (0%)	13 (38%)^b	1 (17%)	3 (14%)	1 (13%)	2 (18%)	0 (0%)	2 (18%)

Data are presented as n (%). Differences between impact of positive and negative PET results were assessed using χ² tests
^aPositive PET > negative PET, P < 0.05
^bNegative PET > positive PET, P < 0.05
PET positron emission tomography, AD Alzheimer’s disease dementia, FTD frontotemporal dementia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis

ISSN: 1758-9193